Menu
Not yet recruiting NCT07718906

Neuromodulation for Behavioral Changes in Neurological Disorders

No phase Interventional Dementia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Focused Ultrasound.
Who it may be relevant to
Registry conditions: Dementia. Basic parameters: 45 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Prospective Early Feasibility Study of Focused Ultrasound Neuromodulation for Emotional Dysregulation Due to Dementia.

Overview

The purpose of this study is to see if a focused ultrasound neuromodulation can be safely and effectively used to treat symptoms of emotional dysregulation such as agitation, irritability and anxiety

Detailed description

This open-label early feasibility study investigates low intensity focussed ultrasound (FUS), in participants with emotional dysregulation due to dementia. The primary objective is to test the safety and feasibility of FUS in this population.

Interventions

  • Device Focused Ultrasound
    Subjects will undergo a single focused ultrasound Neuromodulation of the target brain region

Primary outcome measures

  • Occurrence of Treatment Emergent Adverse Events [Time frame: Week 12 compared to baseline]
Secondary outcome measures (2)
  • Change in behavioral symptoms [Time frame: Week 12 compared to baseline]
  • Changes in Anxiety symptoms [Time frame: Week 12 compared to baseline]

Eligibility criteria

  • Age 45-80 years at time of enrollment.
  • Diagnosis of probable mild-stage neurodegenerative dementia, including Alzheimer's disease (AD), frontotemporal dementia (FTD, including behavioral variant and language variant), or dementia with Lewy bodies (LBD), based on established consensus clinical criteria.
  • Presence of clinically meaningful (in treatment for or recommended for the symptoms) neuropsychiatric or behavioral symptoms including but not limited to anxiety, agitation, depression, irritability, apathy, or disinhibition
  • Able to undergo MRI scanning
  • Adequate auditory and visual abilities to complete study procedures as determined by the investigator.
  • Availability of a study partner (legally authorized representative, caregiver, or family member) who has regular contact with the participant and can provide collateral information and assist with assessments.
  • Ability to provide informed consent, or assent with legally authorized representative (LAR) consent in accordance with WVU IRB policy and applicable West Virginia law. .Currently under the care of a licensed physician, psychiatrist, or neurologist, and agrees to allow communication between investigators/study staff and healthcare providers for purposes of eligibility confirmation and safety monitoring.

Exclusion criteria

  • Moderate to severe dementia (i.e., beyond mild stage).
  • Clinically significant MRI abnormality that may jeopardize participant safety, study conduct, or confound diagnostic assessments.
  • History of clinically significant neurological disorder other than the qualifying dementia diagnosis that could confound evaluation or increase risk.
  • Major psychiatric disorder that would interfere with participation or safety, including psychosis, active suicidal ideation, or severe mood/anxiety disorder requiring immediate intervention.
  • Elevated suicide risk with History of medically verified suicide attempt within the past year.
  • Use of medications that significantly lower the seizure threshold or interfere with neuromodulation safety, as determined by the study physician.
  • Use of investigational drugs or participation in another interventional clinical trial within 30 days prior to screening.
  • Any condition that, in the opinion of the investigator, would interfere with study participation, safety, or interpretation of results.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • WVU Rockefeller Neuroscience Institute — Morgantown

Identifiers

NCT: NCT07718906 · RNI_NMD_EDR

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗